Echo Therapeutics to Present at RedChip Small-Cap Investor ...( FRANKLIN Mass. Feb. 5 /- Echo The...)
| HOME >> BIOLOGY >> TECHNOLOGY |
FRANKLIN, Mass., Feb. 5 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a specialty pharmaceuticals and diabetes management company, announced today that Patrick T. Mooney, M.D, Chairman and Chief Executive Officer, will present at the RedChip Small-Cap Investor Conference on February 7, 2008 at 3:50 pm Mountain Standard Time (5:50 pm Eastern Standard Time). The conference will be held at the Four Seasons Resort in Scottsdale, Arizona. A live video webcast of the presentation will be available on the RedChip Small-Cap Investor Conference website, http://www.visualwebcaster.com/RedChipfeb2008/. A replay of the webcast and the corresponding presentation will be available on Echo Therapeutics' website shortly following the live presentation.
About Echo Therapeutics
Echo Therapeutics is a platform-enabled, specialty pharmaceuticals and
diabetes management company leveraging its expertise in transdermal science
to develop and commercialize non-invasive specialty pharmaceutical products
and medical devices. Echo's Symphony(TM) CTGM System is a next generation
needle- free, wireless, continuous transdermal glucose monitoring (CTGM)
system for diabetes home use and emerging hospital critical care markets.
Symphony is designed to provide on-demand glucose data conveniently,
continuously and cost-effectively. Symphony incorporates Echo's patented
feedback mechanism for optimal skin permeation control and its continuous
transdermal biosensor. With Symphony, Echo is focused on changing the
paradigm of invasive, episodic glucose testing in diabetes home use and
hospital critical care settings. Echo is also marshalling the potential of
its patented AzoneTS(TM) transdermal drug delivery technology to build an
extensive pipeline of advanced topical reformulations of FDA-approved
products in accordance with the FDA's Section 505(b)(2) guidelines. Echo
has sub
'/>"/>
| SOURCE Echo Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
2. Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease
3. Synosia Therapeutics Appoints Chief Financial Officer to New Company Headquarters in Switzerland
4. Taligen Therapeutics Secures Series B Financing
5. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008
7. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
8. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
9. CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
10. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |